Why the study?
The haemodynamic effects of istaroxime in SCAI stage B cardiogenic shock due to acute decompensated heart failure had not been evaluated.
Does a 60-hour intravenous infusion of istaroxime improve invasive haemodynamic measures and biventricular contractility compared with placebo in patients hospitalized with ADHF-related SCAI stage B cardiogenic shock?
Does a 60-hour intravenous infusion of istaroxime improve invasive haemodynamic measures and biventricular contractility compared with placebo in patients hospitalized with ADHF-related SCAI stage B cardiogenic shock?
In patients with ADHF-related SCAI stage B cardiogenic shock, a 60-hour istaroxime infusion significantly improved left ventricular performance (API, LVSWI, LV Ees), reduced right ventricular afterload (increased PA compliance, reduced PA elastance), and stabilized right ventricular contractility compared with placebo.
Answers are grounded in this paper and cite their sources.
Supports hemodynamic gains with istaroxime in SCAI stage B shock; extends RCT data to invasive RV and PA metrics.
AIMS: The haemodynamic effects of istaroxime in SCAI stage B cardiogenic shock (CS) due to acute decompensated heart failure (ADHF) have not been evaluated. We assessed the impact of istaroxime on specific invasively-obtained haemodynamic measures. METHODS AND RESULTS: In the SEISMiC extension study, 30 patients with ADHF-related SCAI stage B CS were randomized to 60-h intravenous infusion of either placebo (n = 11) or istaroxime at maximum 0.5-1.0 μg/kg/min (n = 19). In this post hoc analysis, invasively-obtained haemodynamic measures, simulated group-averaged pressure-volume (PV) loops, and end-systolic elastance (Ees), derived from individual-patient PV relationships, were compared between istaroxime- and placebo-treated patients. Compared with placebo, patients randomized to istaroxime for 48-60 h had greater increases in aortic pulsatility index (API) and left ventricular (LV) stroke work index (LVSWI) at 6, 12, 24, and 48 h; and greater increase in pulmonary artery (PA) compliance and reduction in PA elastance at 48 h. At group-averaged PV loop analysis, LV contractility remained stable and right ventricular (RV) contractility tended to deteriorate over time with placebo, whereas LV contractility improved and RV contractility tended to be stabilized with istaroxime. Greater increases in both LV Ees and RV Ees were observed with istaroxime versus placebo from baseline to 48 h. CONCLUSIONS: In patients with ADHF-pre-CS, istaroxime at doses up to 1.0 μg/kg/min for up to 60 h was associated with sustained improvements in measures of LV performance (API and LVSWI), in parallel with increase in PA compliance and reduction in PA elastance at 48 h. As compared with placebo, istaroxime improved LV contractility and preserved RV contractility, which deteriorated on placebo, over time.
No takes yet. Share an insight, caveat, or question.
Pagnesi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: